News & Views
Significant Appointment for Company Transition Phase
May 10 2019 Read 185 Times
Biopharmaceutical company Enterprise Therapeutics Ltd, a developer of therapies for patients with respiratory disease, has appointed Amit D. Munshi as Non-Executive Chairman of the Board of Directors. His commercial pharma experience will strengthen the company’s leadership team as it transitions to a clinical stage development company.
With more than 28 years of global biopharmaceutical industry experience in management, product and portfolio development, Mr Munshi is currently Director, President and Chief Executive Officer of Arena Pharmaceuticals which has a proprietary pipeline in mid-late stage clinical development. He also served as President and Chief Executive Officer of Epirus Biopharmaceuticals and Percivia LLC, was a co-founder and Chief Business Officer of Kythera Biopharmaceuticals and held multiple leadership positions at Amgen.
He has a BS in Economics and a BA. in History from the University of California, Riverside and an MBA from the Peter F. Drucker School of Management at Claremont Graduate University.
Dr John Ford, CEO, Enterprise Therapeutics, said: “We are delighted that Amit has chosen to join as Chairman at this exciting time for the Company, as we prepare to take our two lead programmes into the clinic in the next 12 months. Amit brings a wealth of experience in product development, portfolio management and commercial strategy in both the US and EU that will be critical in driving the Company through the next phase of its development.”
Amit D. Munshi, Chairman, Enterprise Therapeutics added: “Enterprise is led by an impressive management team with significant expertise and experience, and is backed by a high-profile syndicate of investors. I believe the Company and its therapeutic programmes have real potential to make a difference to the lives of respiratory disease patients.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...
View all digital editions
Jun 02 2019 Atlanta, GA, USA
Jun 10 2019 Berlin, Germany
Jun 12 2019 Shanghai, China
Jun 16 2019 Milan, Italy
Jun 26 2019 Basel, Switzerland